ClinicalTrials.gg
CompletedNCT06658626Updated Oct 26, 2024

A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)

A Phase 1 interventional study of [¹⁴C]Enlicitide chloride in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.
  • Registered 1 year 7 months after the study started (first participant enrolled Mar 2023, registered Oct 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

The purpose of this study is to learn what happens to enlicitide chloride labeled with [¹⁴C] in a person's body over time. A label can be added to a study medicine to trace it in a person's body.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is in good health.
  • Has a ≥18 and ≤32 kg/m\^2, inclusive.

Exclusion criteria

Exclusion Criteria:

  • Has a history of cancer.
  • Has positive tests for surface antigen, antibodies or .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    [¹⁴C]Enlicitide chloride

    Participants will receive a single dose of \[¹⁴C\]enlicitide chloride on Day 1.

    Drug: [¹⁴C]Enlicitide chloride

Interventions

06

What researchers measure

Primary outcomes

  1. Cumulative Amount of Radioactivity Excreted in Urine (Aeu)

    Urine samples will be collected to determine the Aeu of \[¹⁴C\]enlicitide chloride.

    Time frame: At designated timepoints (up to 15 days)

  2. Cumulative Amount of Radioactivity Excreted in Feces (Aef)

    Fecal samples will be collected to determine the Aef of \[¹⁴C\]enlicitide chloride.

    Time frame: At designated timepoints (up to 15 days)

  3. Cumulative Percentage of Radioactivity Excreted in Urine (feu)

    Urine samples will be collected to determine the feu of \[¹⁴C\]enlicitide chloride.

    Time frame: At designated timepoints (up to 15 days)

  4. Cumulative Percentage of Radioactivity Excreted in Feces (fef)

    Fecal samples will be collected to determine the fef of \[¹⁴C\]enlicitide chloride.

    Time frame: At designated timepoints (up to 15 days)

  5. Plasma Enlicitide Chloride: Area Under the Concentration-Time Curve from Time 0 to the Last Measurable Concentration (AUC0-t)

    Plasma samples will be collected to determine the AUC0-t of enlicitide chloride.

    Time frame: At designated timepoints (up to 15 days)

  6. Plasma Enlicitide Chloride: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-inf)

    Plasma samples will be collected to determine the AUC0-inf of enlicitide chloride.

    Time frame: At designated timepoints (up to 15 days)

  7. Plasma Enlicitide Chloride: Maximum Plasma Concentration (Cmax)

    Plasma samples will be collected to determine the Cmax of enlicitide chloride.

    Time frame: At designated timepoints (up to 15 days)

  8. Plasma Enlicitide Chloride: Apparent Terminal Half-life (t1/2)

    Plasma samples will be collected to determine the t1/2 of enlicitide chloride.

    Time frame: At designated timepoints (up to 15 days)

  9. Plasma Enlicitide Chloride: Time to Maximum Plasma Concentration (Tmax)

    Plasma samples will be collected to determine the Tmax of enlicitide chloride.

    Time frame: At designated timepoints (up to 15 days)

  10. Plasma Total Reactivity: AUC0-t

    Plasma samples will be collected to determine the AUC0-t of total reactivity.

    Time frame: At designated timepoints (up to 15 days)

  11. Plasma Total Reactivity: AUC0-inf

    Plasma samples will be collected to determine the AUC0-inf of total reactivity.

    Time frame: At designated timepoints (up to 15 days)

  12. Plasma Total Reactivity: Cmax

    Plasma samples will be collected to determine the Cmax of total reactivity.

    Time frame: At designated timepoints (up to 15 days)

  13. Plasma Total Reactivity: t1/2

    Plasma samples will be collected to determine the t1/2 of total reactivity.

    Time frame: At designated timepoints (up to 15 days)

  14. Plasma Total Reactivity: Tmax

    Plasma samples will be collected to determine the Tmax of total reactivity.

    Time frame: At designated timepoints (up to 15 days)

  15. Enlicitide Chloride to Total Radioactivity Ratio of Area Under the Concentration-Time Curve from Time 0 to the Last Detectable Sample (enlicitide chloride AUC0-x/total radioactivity AUC0-x)

    Plasma samples will be collected to determine the enlicitide chloride AUC0-x/total radioactivity AUC0-x.

    Time frame: At designated timepoints (up to 15 days)

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 29 days

  2. Number of Participants Who Discontinue the Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 29 days

07

Study locations

1 site
  • Labcorp Clinical Research Unit Inc. (Site 0001)
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Aug 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2024
First posted
Oct 26, 2024
StartActual
Mar 10, 2023
Primary completionActual
Aug 2, 2023
CompletionActual
Aug 2, 2023
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06658626
Responsible party
Sponsor
First posted
Oct 26, 2024
Start date
Mar 10, 2023
Primary completion
Aug 2, 2023
Completion
Aug 2, 2023
Last update
Oct 26, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enlicitide chloride

Start the discussion